Diploma (LON:DPLM) Receives Buy Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of Diploma (LON:DPLM) in a research report sent to investors on Friday morning, MarketBeat reports. They currently have a GBX 5,100 ($63.93) target price on the stock.

Separately, Shore Capital cut Diploma to a “hold” rating in a report on Tuesday.

Diploma Stock Performance

DPLM opened at GBX 4,466 ($55.99) on Friday. The company has a debt-to-equity ratio of 45.69, a quick ratio of 0.80 and a current ratio of 2.27. The stock has a market capitalization of £5.99 billion, a price-to-earnings ratio of 5,179.07, a PEG ratio of 2.82 and a beta of 0.75. The company has a fifty day moving average of GBX 4,384.83 and a 200 day moving average of GBX 4,265.19. Diploma has a fifty-two week low of GBX 3,200 ($40.12) and a fifty-two week high of GBX 4,653 ($58.33).

Diploma Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, January 31st. Stockholders of record on Thursday, January 16th will be paid a GBX 42 ($0.53) dividend. This represents a dividend yield of 0.93%. This is a positive change from Diploma’s previous dividend of $17.30. The ex-dividend date is Thursday, January 16th. Diploma’s dividend payout ratio (DPR) is presently 6,627.91%.

Insider Transactions at Diploma

In other Diploma news, insider Johnny Thomson sold 26,794 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of GBX 4,536 ($56.86), for a total transaction of £1,215,375.84 ($1,523,600.15). Company insiders own 0.52% of the company’s stock.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.